tiprankstipranks
Hims & Hers Health, Inc. (HIMS)
:HIMS
US Market

Hims & Hers Health (HIMS) Earnings Dates, Call Summary & Reports

Compare
4,568 Followers

Earnings Data

Report Date
May 12, 2025
TBA Not Confirmed
Period Ending
2025 (Q1)
Consensus EPS Forecast
0.12
Last Year’s EPS
0.05
Same Quarter Last Year
Based on 13 Analysts Ratings
---

Earnings Call Summary

Earnings Call Date:Feb 24, 2025
|
% Change Since: -32.27%
|
Next Earnings Date:May 12, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted strong revenue and subscriber growth, along with strategic acquisitions and innovations in personalized treatment offerings. However, challenges such as declining gross margins, potential regulatory issues, and transitions in product offerings present notable risks. Overall, the positives in growth and strategic direction are tempered by these operational and regulatory concerns.
Company Guidance
During the Hims & Hers Fourth Quarter 2024 Earnings Call, the company provided guidance highlighting significant growth metrics and future projections. Revenue for the fourth quarter reached $481 million, with a substantial year-over-year growth of 95%, culminating in $1.5 billion for the fiscal year, representing a 69% increase from the previous year. The company anticipates revenue for 2025 to range between $2.3 billion to $2.4 billion, indicating a further increase of 56% to 63%. Adjusted EBITDA for 2025 is expected to be between $270 million and $320 million, with an adjusted EBITDA margin projected at 13%. The company reported a 45% increase in total subscribers, totaling over 2.2 million by the end of the year. Non-GLP-1 offerings contributed $1.2 billion, reflecting a 43% increase, and the weight loss platform alone is expected to generate at least $725 million in 2025. Hims & Hers plans to continue investing in expanding their diagnostic capabilities and technology infrastructure to enhance customer personalization and engagement, aiming for a long-term revenue retention rate above 85% and targeting margins of at least 20% by 2030.
Record Revenue Growth
Revenue was $481 million for Q4 and $1.5 billion for the 2024 fiscal year, representing year-over-year growth of 95% for Q4 and 69% for the fiscal year.
Subscriber Growth
Total subscribers increased 45% to over 2.2 million in Q4, with over 55% subscribing to at least one personalized solution.
Expansion of Personalized Treatments
Unique form factors and personalized dosages are unlocking growth, with subscribers in men's and women's dermatology growing over 55% and 100% year-over-year, respectively.
First Full Year of GAAP Profitability
Net income was $26 million in Q4 and $126 million for the full year, marking the company's first full year of GAAP profitability.
Strong Cash Flow
The company generated nearly $60 million of free cash flow in Q4, totaling nearly $200 million for the year.
Innovative Acquisitions
Acquired whole body lab testing facilities and a peptide facility to enhance personalization and innovation in health care services.
---

Hims & Hers Health (HIMS) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

HIMS Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
May 12, 20252025 (Q1)
0.12 / -
0.05
Feb 24, 20252024 (Q4)
0.11 / 0.11
0.011000.00% (+0.10)
Nov 04, 20242024 (Q3)
0.11 / 0.32
-0.04900.00% (+0.36)
Aug 05, 20242024 (Q2)
0.04 / 0.06
-0.03300.00% (+0.09)
May 06, 20242024 (Q1)
0.01 / 0.05
-0.05200.00% (+0.10)
Feb 26, 20242023 (Q4)
-0.02 / 0.01
-0.05120.00% (+0.06)
Nov 06, 20232023 (Q3)
-0.04 / -0.04
-0.0955.56% (+0.05)
Aug 07, 20232023 (Q2)
-0.05 / -0.03
-0.170.00% (+0.07)
May 08, 20232023 (Q1)
-0.02 / -0.05
-0.0837.50% (+0.03)
Feb 27, 20232022 (Q4)
-0.06 / -0.05
-0.1566.67% (+0.10)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---

HIMS Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Feb 24, 2025$51.31$39.86-22.32%
Nov 04, 2024$20.76$20.64-0.58%
Aug 05, 2024$17.84$16.88-5.38%
May 06, 2024$11.65$12.35+6.01%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---

FAQ

When does Hims & Hers Health, Inc. (HIMS) report earnings?
Hims & Hers Health, Inc. (HIMS) is schdueled to report earning on May 12, 2025, TBA Not Confirmed.
    What is Hims & Hers Health, Inc. (HIMS) earnings time?
    Hims & Hers Health, Inc. (HIMS) earnings time is at May 12, 2025, TBA Not Confirmed.
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is HIMS EPS forecast?
          HIMS EPS forecast for the fiscal quarter 2025 (Q1) is 0.12.
            ---

            Hims & Hers Health (HIMS) Earnings News

            HIMS Earnings: Hims & Hers Skyrockets on Q4 Beat
            Premium
            Market News
            HIMS Earnings: Hims & Hers Skyrockets on Q4 Beat
            1y ago
            Hims & Hers (NYSE:HIMS) Soars on Healthy Q3 Performance
            Premium
            Market News
            Hims & Hers (NYSE:HIMS) Soars on Healthy Q3 Performance
            1y ago
            Hims & Hers (NYSE:HIMS) Soars On Robust Q2 Outing
            Premium
            Market News
            Hims & Hers (NYSE:HIMS) Soars On Robust Q2 Outing
            2y ago
            HIMS Up after Upbeat Outlook
            Premium
            Market News
            HIMS Up after Upbeat Outlook
            2y ago
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis